3D bioprinted GelMA platform for the production of lung tumor spheroids

The study proposes a platform for the formation and culture of non-small cell lung cancer (NSCLC) spheroids, to obtain an in vitro model suitable for drug and therapy testing. To achieve that, traditional cell culture is compared to methacrylated gelatin (GelMA) 3D bioprinting, in order to explore not only the potential of the matrix itself, but also the impact of different architectures on spheroid formation. Starting from a systematic analysis, where GelMA concentration, methacrylation degree and cell seeding concentration is set; three different architectures (round, ring and grid) are analyzed in terms of spheroid formation and growth, using 3D bioprinting. The study reveals that Very High GelMA 7.5% w/v formulation, with single cells dispersed in, is the best bioink to obtain NSCLC spheroids. Moreover, grid architecture performs in the best way, because of the highest volume-surface area ratio. The designed GelMA platform can be used as a powerful in vitro tool for drug testing and therapy screening, that can be designed playing with four different parameters: cell concentration, GelMA methacrylation degree, GelMA concentration and geometry.